Effect of dotinurad on proteinuria in patients with hyperuricemia.

Effect of dotinurad on proteinuria in patients with hyperuricemia. - Effect of dotinurad on proteinuria in patients with hyperuricemia.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060280

Enrollment

Registered

2026-01-08

Start date

2021-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hyperuricemia and proteinuria

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who visited the outpatient department of Ibaraki Prefectural Central Hospital/Ibaraki Regional Cancer Center between April 2021 and September 2024 and were prescribed dotinurad for hyperuricemia were included. Among these, patients for whom serum uric acid levels, serum creatinine levels, and UPCR could be evaluated at 1, 3, 6, and 12 months post-administration and whose UPCR was 0.15 g/gCr or higher were included.

Exclusion criteria

Exclusion criteria: Patients who had a new intervention of other drugs after the start of dothinurad were excluded.

Design outcomes

Primary

Measure	Time frame
Proteinuria (urine protein/creatinine ratio) over 12 months following dotinurad administration	—

Secondary

Measure	Time frame
Serum uric acid levels and eGFR over 12 months following dotinurad administration	—

Countries

Japan

Contacts

Public ContactTeppei Motomura

Ibaraki prefectural central hospital,Ibraki cancer center Nephrology

teppei621621@gmail.com0296771121

Outcome results